CD19/BCMA-targeted CAR-T lentiviral vector drug

PreclinicalCell therapy

CD19/BCMA-targeted CAR-T lentiviral vector drug is one of 39 small molecule programs targeting Autoimmune Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Autoimmune DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Blincyto

Amgen

Phase 2

1 5

Cytosar

Teva

Phase 2

1 6

Soliris

Rayos

2 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 9

Vepesid

AAvyxa

Phase 2

1 10

Bicnu

MMelissa K Accordino

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

N/ANot yet recruiting

Autoimmune Disease

NCT07490951

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases

Not yet recruiting·SShenzhen Genocury Biotech Co., Ltd.·N/A·NCT07490951·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD19/BCMA-targeted CAR-T lentiviral vector drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19/BCMA-targeted CAR-T lentiviral vector drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19/BCMA-targeted CAR-T lentiviral vector drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Genocury Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: SShenzhen Genocury Biotech Co., Ltd.

CD19/BCMA-targeted CAR-T lentiviral vector drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News